Acylation-stimulating protein precursor proteins in adipose tissue in human obesity

Metabolism: Clinical and Experimental

Volumn 52, Issue 10, 2003, Pages 1360-1366

  Xia, Zhunan ^a   Cianflone, Katherine ^b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLATION STIMULATING PROTEIN; ADIPSIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; MESSENGER RNA; PROTEIN PRECURSOR; COMPLEMENT FACTOR D; COMPLEMENT FACTOR D, HUMAN; SERINE PROTEINASE;

ACYLATION; ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENDER; HUMAN; HUMAN TISSUE; MALE; OBESITY; OMENTUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SUBCUTANEOUS TISSUE; BODY CONSTITUTION; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; STATISTICAL MODEL;

ADIPOSE TISSUE; ADULT; BODY CONSTITUTION; BODY MASS INDEX; COMPLEMENT C3; COMPLEMENT FACTOR B; COMPLEMENT FACTOR D; FEMALE; GENE EXPRESSION; HUMANS; LINEAR MODELS; MALE; OBESITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SEX FACTORS;

EID: 0242300658     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(03)00254-3     Document Type: Article

References (65)

1. Ebeling P, Teppo AM, Koistinen HA, et al: Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with type II Diabetes. Diabetologia 42:1433-1438, 1999
2. Ylitalo K, Porkka KV, Meri S, et al: Serum complement and familial combined hyperlipidemia. Atherosclerosis 129:271-277, 1997
3. Muscari A, Bozzoli C, Puddu GM, et al: Association of serum C3 levels with the risk of myocardial infarction. Am J Med 98:357-364, 1995
4. Ylitalo K, Pajukanta P, Meri S, et al: Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21:838-843, 2001
5. Ebeling P, Teppo AM, Koistinen HA, et al: Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metabolism 50:283-287, 2001
6. Weyer C, Tataranni PA, Pratley RE: Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 23:779-785, 2000
7. Pomeroy C, Mitchell J, Eckert E, et al: Effect of body weight and calorie restriction on serum complement proteins, including factor D/adipsin: Studies in anorexia nervosa and obesity. Clin Exp Immunol 108:507-515, 1997
8. Halkes CJM, Kijk HV, De Jaegere PPT, et al: Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: Effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 21:1526-1530, 2001
9. Muscari A, Massarelli G, Bastagli L, et al: Relationship of serum C3 to fasting insulin risk factors and previous ischemic events in middle-aged men. Eur Heart J 21:1081-1090, 2000
10. Scriba PC, Bauer M, Emmert D, et al: Effects of obesity, total fasting and re-alimentation on L-thyroxine (T4), 3,5,3′-L-triiodothyronine (T3), 3,3′,5′-L-triiodothyronine (rT3), thyroxine binding globulin (TBG), cortisol, thyrotrophin, cortisol binding globulin (CBG), transferrin, alpha 2-haptoglobin and complement C′3 in serum. Acta Endocrinol (Copenh) 91:629-643, 1979
11. Pasquali R, Casimirri F, Melchionda N: Protein metabolism in obese patients during very low-calorie mixed diets containing different amounts of proteins and carbohydrates. Metabolism 36:1141-1148, 1987
12. Fisler JS, Drenick EJ, Blumfield DE, et al: Nitrogen economy during very low calorie reducing diets: Quality and quantity of dietary protein. Am J Clin Nutr 35:471-486, 1982
13. Muscari A, Bozzoli C, Puddu GM, et al: Correlations between serum lipids and complement components in adults without demonstrated atherosclerotic disease. Atherosclerosis 81:111-118, 1990
14. Ipp MM, Minta JO, Gelfand EW: Disorders of the complement system in lipodystrophy. Clin Immunol Immunopathol 7:281-287, 1977
15. Sissons PJG, West RJ, Fallows J, et al: The complement abnormalities of lipodystrophy. N Engl J Med 294:461-465, 1976
16. Tanuma Y, Ohi H, Hatano M: Two types of C3 nephritic factor: Properdin-dependent C3NeF and properdin-independent C3NeF. Clin Immunol Immunopathol 56:226-238, 1990
17. Skattum L, Martensson U, Sjoholm AG: Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): Clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies. J Intern Med 242:455-464, 1997
18. Morimoto Y, Taniguchi H, Yamashiro Y, et al: Complements in diabetes mellitus: Activation of complement system evidenced by C3d elevation in IDDM. Diabetes Res Clin Pract 5:309-312, 1988
19. McMurray DN, Beskitt PA, Newmark SR: Immunologic status in severe obesity. Int J Obesity 6:61-68, 1982
20. Ledue TB, Neveux LM, Palomaki GE, et al: The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta 223:73-82, 1993
21. Mantov S, Raev D: Addictive effect of diabetes and systemic hypertension on the immune mechanisms of atherosclerosis. Int J Cardiol 56:145-148, 1996
22. Bozzoli C, Muscari A, Puddu GM, et al: Association of serum C3 and essential hypertension. G Ital Cardiol 22:1361-1366, 1992
23. Uza G, Cristea A, Cucuianu MP: Increased level of the complement C3 protein in endogenous hypertriglyceridemia. J Clin Lab Immunol 8:101-105, 1982
24. McMillan DE: Elevation of complement components in diabetes mellitus. Diabetes Metab 6:265-270, 1980
25. Nemeth A, Szakmary K, Kramer J, et al: Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. Eur J Clin Chem Clin Biochem 33:799-804, 1995
26. Alper CA, Johnson AM, Birtch AG, et al: Human C3: Evidence for the liver as the primary site of synthesis. Science 163:286-288, 1969
27. Peake PW, O'Grady S, Pussell BA, et al: Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur J Clin Invest 27:922-927, 1997
28. Cianflone K, Maslowska M: Differentiation induced production of ASP in human adipocytes. Eur J Clin Invest 25:817-825, 1995
29. Choy LN, Spiegelman BM: Regulation of alternative pathway activation and C3a production by adipose cells. Obes Res 4:521-532, 1996
30. Rieusset J, Auwerx J, Vidal H: Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265:265-271, 1999
31. Imbeault P, Vidal H, Tremblay A, et al: Age-related differences in messenger ribonucleic acid expression of key proteins involved in adipose cell differentiation and metabolism. J Clin Endocrinol Metab 86:828-833, 2001
32. Dusserre E, Moulin P, Vidal H: Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta 1500:88-96, 2000
33. Koistinen HA, Vidal H, Karonen SL, et al: Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol 21:1034-1039, 2001
34. Cianflone K, Sniderman AD, Kalant D, et al.: Response of plasma ASP to a prolonged fast. Int J Obesity 19:604-609, 1995
35. Weyer C, Partley RE: Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. Obes Res 7:444-452, 1999
36. Maslowska M, Vu H, Phelis S, et al.: Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest 29:679-686, 1999
37. Cianflone K, Zhang XJ, Genest J Jr, et al: Plasma acylation stimulating protein in coronary artery disease. Arterioscler Thromb Vasc Biol 17:1239-1244, 1997
38. Matthan NR, Cianflone K, Lichtenstein AH et al: Hydrogenated fat consumption affects acylation-stimulating protein levels and cholesterol esterification rates in moderately hypercholesterolemic women. J Lipid Res 42:1841-1848, 2001
39. Ozata M, Gungor D, Turan M, et al: Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol Metab 86:3659-3664, 2001
40. Ozata M, Ortenli C, Culec M, et al: Increased fasting plasma acylation-stimulating protein concentrations in nephrotic syndrome. J Clin Endocrinol Metab 87:853-858, 2002
41. Charlesworth JA, Peake PW, Campbell LV, et al: The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers. Int J Obes Relat Metab Disord 22:1096-1102, 1998
42. Titov LP, Korvigo GV, Kharitonik GD, et al: Levels of various components of the classical and alternative pathways of complement activation in diabetes mellitus patients. Probl Endokrinol (Mosk) 33:9-12, 1987
43. Alessi MC, Parrot G, Guenoun E, et al: Relation between plasma PAI activity and adipsin levels. Thromb Haemost 74:1200-1202, 1995 (letter)
44. Mavri A, Stegnar M, Krebs M, et al: Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 19:1582-1587, 1999
45. Napolitano A, Lowell BB, Damm D, et al: Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int J Obes Relat Metab Disord 18:213-218, 1994
46. Montague CT, Prins JB, Sanders L, et al: Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47:1384-1391, 1998
47. Choy LN, Rosen BS, Spiegelman BM: Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 267:12736-12741, 1992
48. Cianflone K, Roncari DAK, Maslowska M, et al: The adipsin/acylation stimulating protein system in human adipocytes: Regulation of triacylglycerol synthesis. Biochemistry 33:9489-9495, 1994
49. Arner P: Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med 27:435-438, 1995
50. Bouchard C, Despres KP, Mauriege P: Genetic and nongenetic determinants of regional fat distribution. Endocr Rev 14:72-93, 1993
51. Bjorntorp P: The regulation of adipose tissue distribution in humans. Int J Obesity 20:291-302, 1996
52. Bjorntorp P: Metabolic implications of body fat distribution. Diabetes Care 14:1132-1143, 1991
53. Lapidus L, Bengtsson C, Larsson B, et al: Distribution of adipose tissue and risk of cardiovascular disease and death: A 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 289:1257-1261, 1984
54. Boggs RD, McCumbee WD, Cobbs SL, et al: Increased expression of complement component C3 in the plasma of obese Zucker fa and LA/N fa(f) rats compared with their lean counterparts. Obes Res 6:361-367, 1998
55. Saleh J, Summers LKM, Cianflone K, et al: Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J Lipid Res 39:884-891, 1998
56. Kalant D, Phelis S, Fielding BA, et al: Increased postprandial fatty acid trapping in subcutaneous adipose tissue in obese women. J Lipid Res 41;1963-1968, 2000
57. Kalant D, Cain SA, Maslowska M, et al: The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J Biol Chem 278:11123-11129, 2003
58. Cianflone K, Maslowska M, Sniderman AD: Acylation stimulating protein (ASP), an adipocyte autocrine: New directions. Semin Cell Dev Biol 10:31-41, 1999
59. Saleh J, Christou N, Cianflone K: Regional specificity of ASP binding in human adipose tissue. Am J Physiol 276:E815-E821, 1999
60. Van Harmelen V, Reynisdottir S, Cianflone K, et al: Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 274:18243-18251, 1999
61. Maslowska M, Sniderman AD, McLean LD, et al: Regional differences in triacylglycerol synthesis in adipose tissue. J Lipid Res 34:219-228, 1993
62. Walsh MJ, Sniderman AD, Cianflone K, et al: The effect of ASP on the adipocyte of the morbidly obese. J Surg Res 46:470-473, 1989
63. Castro Cabezas M, Erkelens DW, Lock LA, et al: Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides. Eur J Clin Invest 24:669-678, 1994
64. Genest J, Sniderman AD, Cianflonez K, et al: Hyperapobetalipoproteinemia: Plasma lipoprotein responses to oral fat load. Arteriosclerosis 6:297-304, 1986
65. Zhang XJ, Cianflone K, Genest J, et al: Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB. Eur J Clin Invest 28:730-739, 1998